Background
Methods
Study population
Measures
Adverse childhood and adulthood experiences
Ascertainment of incident CVD events
Other covariates
Statistical analysis
Results
Characteristics of the study population
Characteristics | Total | Number of ACEs indicators (N = 5836) | |||||
---|---|---|---|---|---|---|---|
0 (n = 1137) | 1 (n = 2095) | 2 (n = 1388) | 3 (n = 821) | ≥ 4 (n = 395) | P valuea | ||
Age, mean (SD), years | 59.6 (8.2) | 56.3 (8.3) | 59.8 (7.9) | 60.7 (8.0) | 60.8 (8.2) | 61.4 (7.9) | < 0.001 |
Sex, n (%) | |||||||
Male | 2901 (49.7) | 486 (42.7) | 1080 (51.6) | 723 (52.1) | 414 (50.4) | 198 (50.1) | < 0.001 |
Female | 2935 (50.3) | 651 (57.3) | 1015 (48.4) | 665 (47.9) | 407 (49.6) | 197 (49.9) | |
Residential areab, n (%) | |||||||
Rural | 4799 (82.2) | 879 (77.3) | 1677 (80.0) | 1187 (85.6) | 704 (85.7) | 352 (89.1) | < 0.001 |
Urban | 1036 (17.8) | 258 (22.7) | 418 (20.0) | 200 (14.4) | 117 (14.3) | 43 (10.9) | |
Marital status | |||||||
Married | 4972 (85.2) | 995 (87.5) | 1808 (86.3) | 1166 (84.0) | 681 (82.9) | 322 (81.5) | 0.003 |
Other marital status | 864 (14.8) | 142 (12.5) | 287 (13.7) | 222 (16.0) | 140 (17.1) | 73 (18.5) | |
Educational levelb, n (%) | |||||||
No formal education | 2288 (39.2) | 315 (27.7) | 737 (35.2) | 599 (43.2) | 417 (50.8) | 220 (55.7) | < 0.001e |
Primary school or below | 1348 (23.1) | 231 (20.3) | 504 (24.1) | 342 (24.7) | 185 (22.5) | 86 (21.8) | |
Middle or high school | 2079 (35.6) | 548 (48.2) | 804 (38.4) | 429 (30.9) | 213 (25.9) | 85 (21.5) | |
College or above | 117 (2.0) | 43 (3.8) | 47 (2.2) | 17 (1.2) | 6 (0.7) | 4 (1.0) | |
Smoking statusb, n (%) | |||||||
Nonsmoker | 3509 (62.2) | 770 (69.8) | 1229 (60.6) | 792 (59.3) | 484 (60.9) | 234 (61.3) | < 0.001 |
Former smoker | 398 (7.1) | 60 (5.4) | 142 (7.0) | 107 (8.0) | 58 (7.3) | 31 (8.1) | |
Current smoker | 1735 (30.8) | 273 (24.8) | 656 (32.4) | 436 (32.7) | 253 (31.8) | 117 (30.6) | |
Alcohol consumptionb, n (%) | |||||||
Nondrinker | 3399 (58.7) | 705 (62.7) | 1245 (59.9) | 777 (56.2) | 452 (55.3) | 220 (56.0) | 0.011 |
Former drinker | 504 (8.7) | 92 (8.2) | 176 (8.5) | 115 (8.3) | 84 (10.3) | 37 (9.4) | |
Current drinker | 1891 (32.6) | 328 (29.2) | 656 (31.6) | 490 (35.5) | 281 (34.4) | 136 (34.6) | |
Physical activity (≥ 3 × a week)b, n (%) | |||||||
Yes | 4939 (84.6) | 973 (85.6) | 1786 (85.3) | 1182 (85.2) | 677 (82.5) | 321 (81.3) | 0.088 |
No | 897 (15.4) | 164 (14.4) | 309 (14.7) | 206 (14.8) | 144 (17.5) | 74 (18.7) | |
Health conditions (yes)b, n (%) | |||||||
Diabetes | 258 (4.5) | 51 (4.6) | 87 (4.2) | 69 (5.1) | 33 (4.1) | 18 (4.6) | 0.787 |
Hypertension | 1094 (19.0) | 184 (16.4) | 380 (18.4) | 290 (21.1) | 161 (19.8) | 79 (20.3) | 0.038 |
Dyslipidemia | 407 (7.2) | 83 (7.5) | 149 (7.3) | 92 (6.8) | 48 (6.0) | 35 (9.1) | 0.355 |
Chronic kidney disease | 333 (5.8) | 40 (3.6) | 99 (4.8) | 97 (7.0) | 58 (7.1) | 39 (9.9) | < 0.001 |
History of medication use (yes)b, n (%) | |||||||
Diabetes medications | 181 (3.1) | 30 (2.6) | 64 (3.1) | 45 (3.2) | 25 (3.0) | 17 (4.3) | 0.587 |
Hypertension medications | 812 (13.9) | 135 (11.9) | 301 (14.4) | 208 (15.0) | 110 (13.4) | 58 (14.7) | 0.198 |
Lipid-lowering therapy | 213 (3.6) | 38 (3.6) | 79 (4.0) | 49 (3.7) | 29 (3.7) | 18 (4.9) | 0.836 |
BMIb, kg/m2, mean (SD) | 23.6 (4.2) | 23.9 (3.9) | 23.8 (4.3) | 23.4 (4.2) | 23.3 (4.0) | 22.9 (4.1) | < 0.001 |
Blood pressureb, mm Hg, mean (SD) | |||||||
Systolic pressure | 128.1 (21.4) | 125.4 (18.6) | 128.2 (21.3) | 129.1 (21.2) | 128.3 (21.3) | 130.5 (25.7) | 0.002 |
Diastolic pressure | 75.4 (11.9) | 75.2 (11.6) | 75.5 (11.7) | 75.4 (12.1) | 74.8 (12.1) | 76.0 (12.2) | 0.560 |
Depressive symptoms scorec, mean (SD) | 7.8 (6.1) | 6.5 (5.6) | 7.1 (5.7) | 8.2 (6.1) | 9.4 (6.7) | 10.61 (6.39) | < 0.001 |
Adulthood social support, mean (SD) | 0.4 (0.7) | 0.4 (0.7) | 0.3 (0.7) | 0.4 (0.7) | 0.4 (0.7) | 0.4 (0.7) | 0.021 |
Metabolic biomarkersd | |||||||
Fasting plasma glucose, mg/dL mean (SD) | 109.1 (34.1) | 108.1 (32.2) | 109.5 (36.9) | 110.3 (33.3) | 107.5 (27.7) | 109.3 (39.2) | 0.474 |
HbA1c (%), mean (SD) | 14.5 (2.3) | 14.2 (2.1) | 14.5 (2.3) | 14.5 (2.2) | 14.5 (2.5) | 14.7 (2.6) | 0.301 |
Total Cholesterol, mg/dL, mean (SD), | 192.6 (37.3) | 191.4 (36.4) | 193.0 (37.6) | 193.1 (37.2) | 191.1 (36.7) | 195.9 (39.4) | 0.364 |
Triglyceride, mg/dL, median (IQR) | 103.6 (77.9) | 100.9 (79.7) | 107.1 (82.3) | 103.5 (71.7) | 100.9 (82.3) | 100.0 (81.4) | 0.142 |
High-density lipoprotein, mg/dL, mean (SD) | 51.3 (15.3) | 50.8 (15.0) | 50.4 (15.5) | 52.3 (15.6) | 52.0 (15.2) | 51.8 (14.5) | 0.017 |
Low-density lipoprotein, mg/dL, mean (SD) | 115.8 (34.1) | 115.6 (32.9) | 116.4 (34.5) | 115.4 (33.8) | 114.7 (34.1) | 117.1 (36.9) | 0.802 |
hs-CRP, mg/L, median (IQR) | 1.0 (1.4) | 0.9 (1.5) | 1.0 (1.4) | 1.0 (1.4) | 1.0 (1.6) | 1.0 (1.4) | 0.195 |
eGFR, mL/min/1.73 m2, mean (SD) | 94.4 (14.0) | 97.3 (14.5) | 93.8 (13.6) | 93.6 (14.4) | 93.4 (13.3) | 94.5 (13.3) | < 0.001 |
Associations of ACEs and AAEs with incident CVD
Case, No | Incidence rate, per 1000 person-years | HR (95% CI) | ||||
---|---|---|---|---|---|---|
Model 1 | Model 2 | Model 3 | Model 4 | |||
Cardiovascular disease | ||||||
ACEs indicatorsa (1-unit per increasing) | NA | NA | 1.12 (1.09–1.14) | 1.14 (1.11–1.17) | 1.12 (1.05–1.20) | 1.11 (1.08–1.14) |
No. of ACEs indicators | ||||||
0 | 109 | 24.41 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
1 | 272 | 33.14 | 1.24 (1.13–1.35) | 1.27 (1.16–1.39) | 1.29 (1.17–1.42) | 1.29 (1.17–1.42) |
2 | 204 | 37.78 | 1.37 (1.25–1.51) | 1.45 (1.32–1.60) | 1.39 (1.25–1.54) | 1.39 (1.25–1.54) |
3 | 137 | 42.91 | 1.54 (1.39–1.71) | 1.64 (1.48–1.82) | 1.56 (1.39–1.74) | 1.56 (1.40–1.75) |
≥ 4 | 67 | 43.93 | 1.55 (1.37–1.76) | 1.70 (1.50–1.93) | 1.57 (1.37–1.80) | 1.58 (1.38–1.81) |
AAEs indicatorsa (1-unit per increasing) | NA | NA | 1.21 (1.18–1.24) | 1.22 (1.19–1.25) | 1.18 (1.15–1.22) | 1.19 (1.16–1.22) |
No. of AAEs indicators | ||||||
0 | 427 | 29.31 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
1 | 163 | 36.57 | 1.11 (1.03–1.19) | 1.16 (1.07–1.25) | 1.10 (1.01–1.19) | 1.10 (1.01–1.19) |
2 | 96 | 48.07 | 1.48 (1.35–1.62) | 1.52 (1.38–1.66) | 1.42 (1.29–1.56) | 1.42 (1.29–1.56) |
3 | 74 | 57.19 | 1.90 (1.71–2.10) | 1.94 (1.75–2.15) | 1.66 (1.49–1.85) | 1.67 (1.50–1.86) |
≥ 4 | 29 | 60.80 | 2.00 (1.71–2.33) | 2.07 (1.77–2.42) | 1.99 (1.70–2.34) | 2.00 (1.70–2.35) |
Heart disease | ||||||
ACEs indicatorsa (1-unit per increasing) | NA | NA | 1.08 (1.04–1.11) | 1.10 (1.06–1.14) | 1.06 (1.02–1.10) | 1.06 (1.02–1.10) |
No. of ACEs indicators | ||||||
0 | 62 | 13.88 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
1 | 156 | 19.01 | 1.25 (1.10–1.43) | 1.30 (1.14–1.48) | 1.33 (1.15–1.54) | 1.33 (1.15–1.54) |
2 | 129 | 23.89 | 1.24 (1.08–1.43) | 1.31 (1.14–1.51) | 1.25 (1.07–1.46) | 1.25 (1.07–1.46) |
3 | 85 | 26.62 | 1.39 (1.20–1.62) | 1.49 (1.28–1.74) | 1.42 (1.20–1.68) | 1.42 (1.20–1.67) |
≥ 4 | 43 | 28.20 | 1.41 (1.17–1.70) | 1.55 (1.29–1.87) | 1.37 (1.12–1.68) | 1.37 (1.12–1.68) |
AAEs indicatorsa (1-unit per increasing) | NA | NA | 1.23 (1.19–1.28) | 1.24 (1.20–1.29) | 1.19 (1.15–1.24) | 1.19 (1.15–1.24) |
No. of AAEs indicators | ||||||
0 | 265 | 18.19 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
1 | 96 | 21.54 | 1.20 (1.08–1.34) | 1.25 (1.12–1.40) | 1.17 (1.04–1.32) | 1.17 (1.04–1.32) |
2 | 53 | 26.54 | 1.60 (1.40–1.82) | 1.63 (1.43–1.86) | 1.57 (1.36–1.80) | 1.57 (1.36–1.80) |
3 | 42 | 32.46 | 1.91 (1.65–2.22) | 1.96 (1.69–2.28) | 1.55 (1.32–1.83) | 1.55 (1.31–1.83) |
≥ 4 | 19 | 39.83 | 2.13 (1.71–2.66) | 2.19 (1.75–2.74) | 2.04 (1.61–2.59) | 2.04 (1.61–2.58) |
Stroke | ||||||
ACEs indicatorsa (1-unit per increasing) | NA | NA | 1.16 (1.13–1.19) | 1.18 (1.15–1.22) | 1.16 (1.13–1.20) | 1.17 (1.13–1.20) |
No. of ACEs indicators | ||||||
0 | 52 | 11.86 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
1 | 135 | 16.83 | 1.27 (1.13–1.44) | 1.31 (1.16–1.48) | 1.32 (1.16–1.50) | 1.32 (1.16–1.50) |
2 | 91 | 17.26 | 1.56 (1.38–1.77) | 1.66 (1.46–1.89) | 1.60 (1.40–1.83) | 1.60 (1.40–1.83) |
3 | 61 | 19.70 | 1.72 (1.50–1.97) | 1.84 (1.60–2.11) | 1.76 (1.52–2.04) | 1.76 (1.53–2.04) |
≥ 4 | 30 | 20.30 | 1.79 (1.53–2.10) | 1.98 (1.68–2.33) | 1.86 (1.57–2.21) | 1.87 (1.58–2.22) |
AAEs indicatorsa (1-unit per increasing) | NA | NA | 1.19 (1.15–1.23) | 1.20 (1.16–1.24) | 1.17 (1.13–1.21) | 1.17 (1.13–1.21) |
No. of AAEs indicators | ||||||
0 | 192 | 13.45 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
1 | 81 | 18.59 | 1.06 (0.97–1.17) | 1.12 (1.01–1.23) | 1.06 (0.95–1.17) | 1.06 (0.95–1.17) |
2 | 48 | 24.64 | 1.34 (1.18–1.51) | 1.37 (1.21–1.55) | 1.25 (1.10–1.42) | 1.25 (1.10–1.42) |
3 | 34 | 27.35 | 1.74 (1.53–1.99) | 1.79 (1.57–2.05) | 1.62 (1.41–1.87) | 1.63 (1.42–1.88) |
≥ 4 | 14 | 30.70 | 2.11 (1.74–2.55) | 2.22 (1.83–2.69) | 2.17 (1.78–2.64) | 2.17 (1.78–2.65) |
Mediation analysis of AAEs on associations between ACEs and incident CVD
HR (95% CI)a | Mediation proportion (%) (95% CI) | ||
---|---|---|---|
Unadjusted for AAEs | Adjusted for AAEs | ||
Cardiovascular disease | |||
ACEs indicatorsb (1-unit per increasing) | 1.11 (1.08–1.14) | 1.09 (1.03–1.16) | 17.7 (8.2–34.2) |
No. of ACEs indicators | |||
0 | 1.00 (reference) | 1.00 (reference) | - |
≥ 1 | 1.38 (1.12–1.70) | 1.36 (1.10–1.68) | 4.6 (1.3–15.4) |
Heart disease | |||
ACEs indicatorsb (1-unit per increasing) | 1.06 (1.02–1.10) | 1.04 (0.98–1.08) | 36.7 (4.0–89.0) |
No. of ACEs indicators | |||
0 | 1.00 (reference) | 1.00 (reference) | - |
≥ 1 | 1.32 (1.16–1.51) | 1.30 (1.14–1.49) | 5.6 (1.0–26.1) |
Stroke | |||
ACEs indicatorsb (1-unit per increasing) | 1.17 (1.13–1.20) | 1.15 (1.11–1.18) | 10.9 (4.5–24.0) |
No. of ACEs indicators | |||
0 | 1.00 (reference) | 1.00 (reference) | - |
≥ 1 | 1.51 (1.34–1.70) | 1.49 (1.32–1.68) | 3.3 (0.9–11.9) |